Hansa Biopharma AB
Research Hansa Biopharma AB (HNSA) on Bullrun: market cap SEK 4.25B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHNSA
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 4.25B
- Financial periodQ2 2026
- RevenueSEK 48.10M
- Net income-SEK 260.54M
- Free cash flow-SEK 122.05M
- Gross margin53.6%
Valuation Snapshot
latest market cap is SEK 4.25B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 222.27M | -SEK 534.11M | n/a | 62.4% | n/a | SEK 701.08M | SEK 938.67M | -SEK 88.99M |
| FY2024 | SEK 171.32M | -SEK 807.24M | -SEK 675.00M | 51.2% | -12.85 | SEK 405.28M | SEK 1.06B | -SEK 589.83M |
| FY2023 | SEK 134.09M | -SEK 831.72M | -SEK 755.94M | 52.9% | -15.83 | SEK 732.06M | SEK 844.90M | -SEK 167.88M |
| FY2022 | SEK 154.53M | -SEK 611.13M | -SEK 506.06M | 75.1% | -13.6 | SEK 1.50B | SEK 762.60M | SEK 602.91M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 4.25B | n/a | n/a | n/a |
About Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Hansa Biopharma AB's market cap?
Hansa Biopharma AB's market capitalization is SEK 4.25B.
What does Hansa Biopharma AB do?
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis.